Hard times at drug division Organon have forced Akzo Nobel to cut costs and restructure. As part of this effort, the Dutch conglomerate has implemented an aggressive partnering strategy to maximize the value of its late-stage pharma pipeline. Its potential $370 million pact with Pfizer for the Phase II/III antipsychotic asenapine marks an impressive start, and underscores Akzo's commitment to rebuilding Organon.
Desperate times call for desperate measures. Or in the case of Dutch conglomerate Akzo Nobel NV 's ailing human pharmaceuticals division, Organon NV , they call for Pfizer Inc. 's marketing muscle.
In late October 2003 Organon announced a worldwide co-promotion deal for its novel atypical antipsychotic asenapine, which is entering Phase...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
